Share this article
Share this article
The approval of Ilaris (canakinumab) in the treatment of adult-onset Still s disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening inflammatory disorder.
Ilaris, an interleukin-1 beta inhibitor, provides a new mode of treatment for this disease
which previously had limited options.
1,2
DORVAL, QC, April 29, 2021 /CNW Telbec/ - Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Ilaris
® (canakinumab) for the treatment of active Still s disease, including adult-onset Still s disease (AOSD)
1. AOSD is a rare form of inflammatory arthritis that can be a complex disease with variable presentation and potentially life-threatening complications